It has been about a month since the last earnings report for CVS Health (CVS) . Shares have added about 4.1% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is CVS Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.CVS Health To ...

Key Takeaways CVS Health's MBR fell to 92.8% in Q3 2025 as prior PDR effects and gov business gains lifted results.CVS' improvement stemmed from nonrecurring PDR, favorable prior period development and better gov performance.CVS expects about 91% full-year 2025 MBR, keeping a prudent view of medical cost trends through year-end.CVS Health’s (CVS) Health Care Benefits segment recorded a medical benefit ratio (MBR) of 92.8% in the third quarter of 2025 compared with 95.2% in the prior year. The metric shows t ...

Core Viewpoint - US stocks have experienced a significant uptrend, with the S&P 500 index rising over 35% since its low in April, yet certain outperforming stocks remain undervalued heading into 2026, presenting potential investment opportunities [4][6]. Group 1: CVS Health - CVS Health has seen a remarkable increase in its stock price, climbing over 78% this year, while trading at a forward earnings multiple of just 11x, which is below the S&P 500 average [7][5]. - The company reported strong Q3 financials and raised its earnings guidance, attributing this to the strength in its insurance business [7]. - Technical indicators show CVS stock is above all major moving averages, and the consensus rating is a "strong buy," with a target price suggesting nearly 20% upside potential [8]. - CVS also offers a healthy dividend yield of 3.33%, making it an attractive option for investors [9]. Group 2: Micron Technology - Micron Technology's stock has nearly tripled since the beginning of the year, yet it maintains a modest forward earnings multiple of 12x [10]. - The company is benefiting from a shortage in dynamic random-access memory (DRAM), which is driving earnings growth, and it has a consensus "buy" rating with price targets suggesting nearly 50% upside potential [11][10]. - The demand for chips related to artificial intelligence (AI) further enhances Micron's growth prospects, making it a standout candidate for investment in 2026 [11]. Group 3: Newmont Corporation - Newmont Corporation, the largest gold producer globally, has outperformed the broader market, with its stock valuation at 5x sales, which is attractive compared to peers [12]. - The stock serves as a hedge against market volatility and policy uncertainty, especially with stable gold prices anticipated heading into 2026 [12]. - Newmont offers a dividend yield of 1.1%, appealing to income-focused investors while providing defensive qualities and growth potential outside of tech and healthcare sectors [13].

Core Points - Grafton Resources Inc. has successfully closed a non-brokered private placement, raising gross proceeds of $2,400,000 through the issuance of 4,800,000 units at a price of $0.50 per unit [1][2] - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at $0.80 until November 27, 2027 [1][2] - The proceeds will be used for the acquisition of the Alicahue Copper Project in Chile, exploration activities, option payments, and general corporate purposes [2] Financial Details - The company paid finder's fees totaling $133,784 in cash and issued 267,568 finder's warrants, each allowing the purchase of one common share at $0.80 until November 27, 2027 [3] - The offering is subject to acceptance by the Canadian Securities Exchange and the securities issued are under a four-month hold period expiring on March 28, 2026 [3] Related Party Transactions - Clariden Capital Ltd., owned by J. Campbell Smyth, participated in the offering by purchasing 345,400 units for $172,700, constituting a related party transaction [4][6] - The company is exempt from formal valuation and minority shareholder approval requirements due to the insider participation not exceeding 25% of the company's market capitalization [4] Ownership Changes - Prior to the offering, J. Campbell Smyth owned approximately 13.73% of the company's common shares, which decreased to approximately 11.79% post-offering [7][8] - Mr. Smyth has no current intention to dispose of or acquire further securities of the company, although he may do so depending on market conditions [9]

Group 1: Thanksgiving Closures - Most federal and financial institutions will pause operations on Thanksgiving Day, including banks, post offices, and the stock market (NYSE and Nasdaq) [2] - Major shipping carriers such as United Parcel Service Inc. and FedEx Corp. will suspend standard pickup and delivery services on this day [2] - Retail giants like Walmart Inc., Target Corp., Costco Wholesale Corp., Macy's Inc., and Kohl's Corp. will remain closed on Thanksgiving Day [3] Group 2: Thanksgiving Openings - Many grocery chains, including Kroger Co., Whole Foods, and Sprouts Farmers Market Inc., will be open on Thanksgiving, albeit with reduced hours [4] - Select pharmacies like CVS Health Corp. and Walgreens will operate, but customers should check local store hours as pharmacy counters may be closed [4] Group 3: Black Friday Operations - Business operations will resume on Black Friday, November 28, with banks and post offices reopening for regular service [6] - The stock market will open but will close early at 1 p.m. ET on Black Friday [6] - Major retailers, including Walmart and Target, will open at 6 a.m. for Black Friday deals, marking the start of the shopping season [6]

Core Insights - UnitedHealth Group Incorporated (UNH) and CVS Health Corporation (CVS) are prominent players in the healthcare industry, integrating health insurance, pharmacy services, and care delivery resources to enhance their market reach [1][2] UnitedHealth Group (UNH) - UNH operates through two segments: UnitedHealthcare (insurance benefits) and Optum (virtual care, behavioral health, pharmacy solutions) [2] - As of September 30, 2025, UNH has a market cap of $296.2 billion and serves 50.1 million people, reflecting a 1.6% year-over-year growth [4] - Total revenue for UNH increased by 12% year-over-year in Q3 2025, with UnitedHealthcare growing by 16% and Optum by 8% [5] - UNH ended Q3 2025 with $30.6 billion in cash and short-term investments, with total debt-to-capital at 41.6% [6] - The medical care ratio rose to 89.9% in Q3 2025, up from 85.2% the previous year, indicating rising medical costs [7] - UNH expects revenues between $445.5 billion and $448 billion for 2025, with adjusted net EPS projected at least $16.25 [13] CVS Health Corporation (CVS) - CVS operates through Aetna (insurance), Caremark (pharmacy benefit management), and retail pharmacy segments [2] - CVS has a market cap of $99.6 billion and serves 26.7 million medical members as of September 30, 2025 [9] - Total revenues for CVS rose by 7.8% year-over-year to $102.9 billion in Q3 2025, with adjusted operating income increasing by 35.8% [10] - CVS ended Q3 2025 with $9.1 billion in cash and cash equivalents, with a medical benefit ratio of 92.8% [11] - CVS expects revenues of at least $397.3 billion for 2025, with adjusted EPS projected between $6.55 and $6.65 [14] Comparative Analysis - CVS is currently favored in earnings estimates, with a projected 22.1% increase in earnings for 2025, while UNH's EPS is expected to decline by 41.1% [15] - Valuation metrics show CVS trading at a forward P/E of 11.07X compared to UNH's 18.68X, indicating a more attractive risk-reward profile for CVS [16] - Year-to-date, UNH shares have dropped by 35.5% due to medical cost concerns, while CVS shares have increased by 74.8% [19] Conclusion - UNH remains a significant player in the healthcare sector but faces challenges from rising medical costs and regulatory scrutiny [20] - CVS is showing positive momentum with improved profit margins and consistent earnings beats, presenting a more favorable investment opportunity [21][22]

Core Insights - UnitedHealth Group Incorporated (UNH) and CVS Health Corporation (CVS) are prominent players in the healthcare industry, integrating health insurance, pharmacy services, and care delivery resources to enhance their reach across the U.S. healthcare ecosystem [1] UnitedHealth Group (UNH) - UNH operates through two main segments: UnitedHealthcare (insurance benefits) and Optum (virtual care, behavioral health, pharmacy solutions) [2] - As of September 30, 2025, UNH has a market cap of $296.2 billion and serves 50.1 million people, reflecting a year-over-year growth of 1.6% [4] - Total revenue for UNH increased by 12% year over year in Q3 2025, with UnitedHealthcare growing by 16% and Optum by 8% [5] - UNH ended Q3 2025 with $30.6 billion in cash and short-term investments, with total debt-to-capital at 41.6% [6] - The medical care ratio rose to 89.9% in Q3 2025, up from 85.2% the previous year, indicating rising medical costs [7] - UNH expects revenues between $445.5 billion and $448 billion for 2025, with adjusted net EPS projected at least $16.25 [13] CVS Health Corporation (CVS) - CVS operates through Aetna (insurance), Caremark (pharmacy benefit management), and retail pharmacy segments, focusing on hybrid care services and digital engagement [2][9] - As of September 30, 2025, CVS has a market cap of $99.6 billion and serves 26.7 million medical members [9] - CVS's total revenues rose by 7.8% year over year to $102.9 billion in Q3 2025, with adjusted operating income increasing by 35.8% [10][11] - CVS ended Q3 2025 with $9.1 billion in cash and cash equivalents, with a medical benefit ratio of 92.8% [11] - CVS expects revenues of at least $397.3 billion for 2025, with adjusted EPS projected between $6.55 and $6.65 [14] Comparative Analysis - CVS is currently favored in earnings estimates, with a projected 22.1% increase in earnings for 2025, while UNH's EPS is expected to decline by 41.1% [15] - Valuation metrics favor CVS, trading at a forward P/E of 11.07X compared to UNH's 18.68X, indicating a more attractive risk-reward profile for CVS [16] - Year-to-date, UNH shares have dropped by 35.5%, while CVS shares have increased by 74.8%, outperforming the broader industry [19] Conclusion - UNH remains a significant player in the healthcare sector but faces challenges such as rising medical costs and regulatory scrutiny [20] - CVS is showing improvements in profit margins and consistently beats earnings expectations, presenting a more favorable risk-reward scenario [21][22]

Core Insights - CVS Health and Walmart are leading players in the U.S. Retail Pharmacy market, with CVS operating nearly 9,000 retail pharmacy locations and Walmart being a tech-powered omnichannel retailer [1][2] Revenue Performance - CVS Health reported record revenues of $103 billion for Q3 2025, exceeding estimates by 17.65%, with an 8% year-over-year growth driven by all segments [3] - Walmart's Q3 fiscal 2026 revenues reached $179.5 billion, a 6% increase in constant currency, surpassing estimates by 1.33%, with the International segment growing 11.4% [4] Profitability Comparison - CVS's adjusted operating income for Q3 2025 was approximately $3.5 billion, a 36% increase year-over-year, with adjusted EPS at $1.60, up 47% from the previous year [5] - Walmart's adjusted operating income increased 8% in constant currency, with adjusted EPS rising 7% year-over-year to 62 cents [6] Financial Health Snapshot - CVS generated operating cash flows of approximately $7.2 billion year-to-date, with total debt at $65.84 billion and $2.6 billion returned to shareholders [7] - Walmart reported $10.6 billion in cash and cash equivalents, with net cash from operating activities at $27.5 billion and total debt at $53.1 billion, returning nearly $13 billion to shareholders [8] Future Outlook - CVS expects revenues of at least $397 billion for 2025, raising its EPS outlook to between $6.55 and $6.65 [10] - Walmart forecasts fiscal 2026 constant-currency sales growth between 4.8% and 5.1%, with adjusted EPS expected between $2.58 and $2.63 [11] Price Performance and Valuation - Year-to-date, CVS shares have surged 73.5%, significantly outperforming Walmart's 15.4% growth [14] - CVS is trading at a forward five-year price-to-sales ratio of 0.24, below its median, while Walmart's P/S is 1.13 [15] Estimate Trends - The Zacks Consensus Estimate for CVS's 2025 EPS implies a year-over-year growth of 22.1% to $6.62, with estimates rising by 4.1% in the past 60 days [16] - Walmart's fiscal 2026 EPS consensus has increased by 0.8% to $2.62, representing a 4.4% increase over fiscal 2025 [18] Investment Consideration - Both CVS and Walmart are positioned as major players in the retail pharmacy space, with CVS showing solid momentum and Walmart benefiting from its International segment and e-commerce growth [19]

Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy benefit manager (PBM), This milestone represents Curaechoice’s mission and commitment to reducing prescription drug costs.  Curaechoice members and their families will be able to fill prescriptions through CVS Caremark’s nationwide network of 65,000 pharmacies and retail and mail-order channels beginning Janua ...

当地时间11月20日，CVS Health宣布，董事会已选举总裁兼首席执行官David Joyner担任董事会主席， 该任命将于2026年1月1日生效。此项任命生效后，Michael Mahoney将继续担任董事会首席独立董事， 现任董事会执行主席Roger Farah将继续在董事会任职。 来源：智通财经 ...